Menu Search
Equities

Phaxiam Therapeutics SA

PHXM:PAR

Phaxiam Therapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.76
  • Today's Change-0.076 / -4.14%
  • Shares traded11.16k
  • 1 Year change-59.05%
  • Beta1.7835
Data delayed at least 15 minutes, as of Nov 12 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The 2 analysts offering 12 month price targets for Phaxiam Therapeutics SA have a median target of 5.10, with a high estimate of 5.30 and a low estimate of 4.90. The median estimate represents a 189.77% increase from the last price of 1.76.
High201.1%5.30
Med189.8%5.10
Low178.4%4.90

Earnings history & estimates in EUR

On Mar 28, 2023, earnings of 1.77 per share.
The next earnings announcement is expected on Mar 18, 2025.
Phaxiam Therapeutics SA reported annual 2023 losses of -3.57 per share on Mar 20, 2024.
Average growth rate-912.48%
More ▼

Revenue history & estimates in EUR

of 5.23m. This bettered the 700.00k estimate of the one analyst covering the company. The same period last year the company did not report revenues.
Average growth rate+242.56%
ERYTECH Pharma S.A. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 31.00m.
Average growth rate+131.10%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.